Trillium Reports Second Quarter 2016 Financial Results
On track to report clinical data from TTI-621 program at the end of 2016 IND submitted to initiate a Phase 1 trial with TTI-621 in solid tumors Cash amounted to $60.1 million (CDN) as of June 30, 2016 TORONTO, ONTARIO -- (Marketwired) -- 08/12/16 -- …